etherna immunotherapies

About:

etherna develops mRNA and lipid nanoparticle solutions.

Top Investors: European Commission, EQT Life Sciences, Boehringer Ingelheim Venture Fund, PMV, Omega Funds

Description:

etherna’s mission is to be a technology leader in the development of nucleic acid-based medicines which enables our partners to create new drugs and improve patients’ lives.

Total Funding Amount:

$112M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Niel, Antwerpen, Belgium

Founded Date:

2013-01-01

Contact Email:

info(AT)etherna.be

Founders:

Kris Thielemans

Number of Employees:

51-100

Last Funding Date:

2022-08-23

IPO Status:

Private

Industries: